Rising Imperatives in Cold Chain and Controlled-Temperature Storage
In the life sciences industry, the demand for precision-controlled logistics is surging. Biopharma innovation, the rise of cellular and gene therapies, and regulatory scrutiny require storage and transport solutions that guarantee temperature stability, whether in labs, manufacturing, or clinical supply chains. Facility expansions, infrastructure upgrades, and strategic acquisitions are becoming critical strategies for companies aiming to offer “gold standard” reliability and compliance across the cold chain ecosystem.
Recent industry movements from cold chain pharmaceutical companies emphasize major investments in temperature-controlled facilities, rapid regional expansion, and enhanced crisis resilience. Against this backdrop, Tobin Scientific’s recent announcements, including a new cGMP-compliant warehouse and a major acquisition, highlight how the company is evolving in lockstep with these pivotal supply chain trends.
Expanding Infrastructure: cGMP Storage That Delivers Scale and Redundancy
In mid-July 2025, Tobin Scientific unveiled a new 40,000 sq ft cGMP-compliant warehouse in Wilmington, Massachusetts, just 20 miles north of Boston. The facility features dual –20 °C storage chambers built for full redundancy, high-density racking, validated ambient ranges (15–25 °C), and comprehensive backup power systems.
It marks Tobin’s third such facility in as many years, aligned with its $65 million growth capital raise earlier in 2025.
This expansion underscores a broader industry imperative: the need for geographically dispersed, high-integrity storage hubs. Such infrastructure enables responsiveness to R&D and supply-chain disruptions, supports scalability for biotech and pharma customers, and ensures compliance with standards like cGMP.
As Erik Groszyk, COO at Tobin Scientific, puts it, the company has “created a proven model for rapidly designing and deploying advanced warehouses that provide our clients with precision temperature control at unmatched value.”
Strategic Integration: Acquiring Wakefield to Amplify Scale and Scope
Just weeks later, Tobin announced the acquisition of Wakefield Moving & Storage, a definitive deal adding 300,000 sq ft of warehouse space in New England. Wakefield brings deep expertise in lab relocations, sensitive equipment moves, and secure facility transitions. The acquisition notably broadens Tobin’s industry reach to sectors like semiconductors and defence, while strengthening core services in biotech, pharma, and academic research logistics.
This move reflects a clear trend: integration across cold chain and logistics verticals to offer clients end-to-end solutions under one roof. The integration of Wakefield’s robust capabilities allows Tobin to tailor offerings, from frozen storage to turnkey relocation, without relying on external vendors.
Vertically Integrated Service: Single-Source Solutions in a Fragmented Market
Tobin Scientific defines itself as “the nation’s only fully–integrated single-source provider of life science laboratory relocation and biorepository.” It delivers a comprehensive array of specialized services: frozen biological and cryogenic transportation, laboratory relocation, temperature-controlled storage (ambient, cGMP, ultra-cold), mobile cold rooms, and biorepository management.
Its biorepository services feature a wide temperature envelope, from –196 °C to 4 °C, and include layered power redundancies, 24/7 alarm monitoring, and real-time data logging.
Capital and Growth: Fueling the Infrastructure Build-Out
Supporting this expansion is a strategic $65 million growth capital infusion secured in May 2025, led by Denali Growth Partners, Truck 9 Partners, and backed by Eastern Bank financing. Tobin’s leadership emphasized that this funding will be deployed to scale its cGMP-compliant infrastructure, expand geographically in pharmaceutical hubs, and support further M&A activities across the life sciences supply chain.
This capital-driven acceleration reinforces trends toward rapid scalability in cold chain infrastructure.
The life sciences sector’s push toward precision, reliability, and regulatory fidelity in cold chain logistics is no passing wave; it’s becoming the new baseline. Tobin Scientific is a strong example of how companies can meet these demands head-on through strategic infrastructure, integrated services, and forward-looking investment.
